PatentVest

The first IP intelligence and strategy firm helping visionary companies become tech leaders. A subsidiary of MDB Capital Holdings (NASDAQ: MDBH)

[PatentVest @PatentVest]

Can OpenAI patent ChatGPT?
Everyone says @OpenAI has no patent moat.

We analyzed 69 published patent families to see if that's true.

The answer may surprise you, and so might how its strategy compares with @AnthropicAI.

Read more:
https://t.co/rJVSJ5T5FH

#OpenAI #Patents

[PatentVest @PatentVest]

Everyone is still talking about GLP-1.

Big Pharma is investing in what's next.

Novo Nordisk, @Roche, and GSK committed $10.7B to FGF21 in just six weeks.

Why?

Find out what's driving the next cardiometabolic opportunity:

https://t.co/eprI7fqFiw

#FGF21 #GLP1 #Biotech #Pharma

[PatentVest @PatentVest]

Lilly paid up to $1.925B for Versanis.

@AstraZeneca acquired SixPeaks.

Large pharma isn't just investing in weight loss.

They're investing in what comes after.

👉 Full analysis: https://t.co/weMCZDrYCr

#GLP1 #Obesity #Biotech

[PatentVest @PatentVest]

Most patents are still drafted for allowance.

The next generation will be drafted for scrutiny.

In his latest article, Javier Chamorro, our COO, explains why AI is changing the future of patent prosecution.

Read more:
https://t.co/tvA6qtrjjF #IPStrategy

[PatentVest @PatentVest]

→ 20 programs in development
→ Lilly acquired Versanis for up to $1.925B
→ AstraZeneca acquired SixPeaks
→Valuable GLP-1 combination IP emerging

New PatentVest Pulse:
https://t.co/weMCZDrYCr
#GLP1 #Obesity #Biotech #Pharma

[PatentVest @PatentVest]

The next blockbuster obesity opportunity may not be another GLP-1.
It may be that the therapies are designed to improve GLP-1s.

[PatentVest @PatentVest]

Read full report: https://t.co/weMCZDrYCr

#GLP1 #Obesity #Biotech #Pharma

[PatentVest @PatentVest]

Our latest case study with Docana explores how we helped define freedom-to-operate boundaries, identify competitive whitespace, and build a long-term IP strategy.

Read full case study: https://t.co/LXgUSkh7nd

[PatentVest @PatentVest]

We’ve just published a new case study with Docana on navigating IP strategy in the competitive AI/LLM space.

From patent landscape analysis to freedom-to-operate strategy, the goal was strategic clarity before scaling.

Read more:
https://t.co/LXgUSkh7nd

[PatentVest @PatentVest]

New PV Pulse Report: The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market. https://t.co/2Qhx38YDWL

[PatentVest @PatentVest]

The obesity-drug race may not be won by the best molecule.

It may be won by the best IP.

[PatentVest @PatentVest]

In our latest PatentVest newsletter, our COO, Javier Chamorro, shares how IP strategy, prosecution processes, and AI are reshaping what it means to build defensible patents.

If you're building technology, this is worth a read. 👇

https://t.co/8YOh93sLss

[PatentVest @PatentVest]

We broke down the full landscape, programs, players, and where defensible positions are actually being built in our latest PatentVest Pulse report.

👇Here: https://t.co/7drd9nLMsC

[PatentVest @PatentVest]

The amylin land grab has started 🧵

@novonordisk , @EliLillyandCo , @Roche , @pfizer , @abbvie , @AstraZeneca , @StructureTx , @Viking_VKTX
All building positions.

That level of alignment is rare.

[PatentVest @PatentVest]

Every major pharma company sees it.
That’s why they’re moving now.
Before the landscape locks in.